EANS-News: Annual General Meeting of Marseille-Kliniken AG supports positive
development of the company
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Annual & Special Corporate Meetings
Subtitle: - New supervisory board member Prof. Dr. Enderlein elected
- Expansion of the authorized capital to 18.7 million
- At the request of the administration former board members were not relieved
Hamburg (euro adhoc) - 27 January 2012 - Today´s Annual General Meeting, located
at the company´s headquarter in Hamburg, approved all significant applications
of the administration with a majority of over 90 percent. This represented
approximately 65 percent of the share capital.
On administration´s recommendation, both former directors, Stefan Herzberg and
Dr. Thomas Klaue, were not relieved. Prof. Dr. Dietmar Enderlein was elected to
the Supervisory Board. The long-time expert in the health care industry is
following Mathias Kampmann, who retired on 17 January 2012.
The decision on the creation of new authorized capital was supported by the
major shareholder and the representatives of shareholder protection communities.
Overall, the meeting took place under the close observation of journalists and
numerous experts in health care.
"The decisions of our shareholders will create a reliable basis for our
operational success.", said Michael Thanheiser, chairman of the company.
Further inquiry note:
Christian Hillermann
Hillermann Consulting
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Germany
Tel.: +49-(0)40 / 320 279-10
Fax: +49-(0)40 / 320 279-114
www.marseille-kliniken.com
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: Marseille-Kliniken AG
Alte Jakobstraße 79/80
D-10179 Berlin
phone: +49 (0)30 246 32-400
FAX: +49 (0)30 246 32-401
mail: info@marseille-kliniken.de
WWW: http://www.marseille-kliniken.de
sector: Pharmaceuticals
ISIN: DE0007783003
indexes: CDAX, Classic All Share, Prime All Share
stockmarkets: free trade: Berlin, Düsseldorf, Stuttgart, regulated dealing:
Hamburg, regulated dealing/prime standard: Frankfurt
language: English